October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback